Abstract
Conventionally, cardiac biomarkers are recognized as an essential tool to investigate the presence or progression of various cardiovascular diseases. However, in recent years, data from several clinical trials have successfully sorted out the utility of cardiac biomarkers in diseases that are not primarily regarded as “cardiac diseases,” especially neurological diseases. Results of freshly published trials have endorsed the use of cardiac biomarkers in various forms of stroke and dementia, including Alzheimer’s disease. Alzheimer’s disease is also one of the other CNS conditions where measuring cardiac biomarkers have been found to be useful. Cardiac biomarkers can be helpful in two ways. Firstly, to assess the secondary involvement of the heart during the progression of the primary disease. Secondly, they can be useful in the diagnosis and prognosis of the primary condition itself. In this short review, we have collected encouraging results from recent studies that show the importance of the most widely recognized cardiac biomarkers in two of the most prominent neurological diseases of the current world, i.e., stroke and dementia.
Keywords: Cardiac biomarker, BNP, troponin, Alzheimer's disease, stroke, pneumonia.
CNS & Neurological Disorders - Drug Targets
Title:Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations
Volume: 20 Issue: 8
Author(s): Shahzad Khan*Mohammad Amjad Kamal
Affiliation:
- Department of Pathophysiology, Wuhan University School of Medicine, Hubei, Wuhan 430071,China
Keywords: Cardiac biomarker, BNP, troponin, Alzheimer's disease, stroke, pneumonia.
Abstract: Conventionally, cardiac biomarkers are recognized as an essential tool to investigate the presence or progression of various cardiovascular diseases. However, in recent years, data from several clinical trials have successfully sorted out the utility of cardiac biomarkers in diseases that are not primarily regarded as “cardiac diseases,” especially neurological diseases. Results of freshly published trials have endorsed the use of cardiac biomarkers in various forms of stroke and dementia, including Alzheimer’s disease. Alzheimer’s disease is also one of the other CNS conditions where measuring cardiac biomarkers have been found to be useful. Cardiac biomarkers can be helpful in two ways. Firstly, to assess the secondary involvement of the heart during the progression of the primary disease. Secondly, they can be useful in the diagnosis and prognosis of the primary condition itself. In this short review, we have collected encouraging results from recent studies that show the importance of the most widely recognized cardiac biomarkers in two of the most prominent neurological diseases of the current world, i.e., stroke and dementia.
Export Options
About this article
Cite this article as:
Khan Shahzad *, Kamal Amjad Mohammad , Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations, CNS & Neurological Disorders - Drug Targets 2021; 20 (8) . https://dx.doi.org/10.2174/1871527319666201005171003
DOI https://dx.doi.org/10.2174/1871527319666201005171003 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Risk Factors for Development of Heart Failure
Current Cardiology Reviews Cardiovascular Disease in Antiphospholipid Syndrome
Current Vascular Pharmacology HIV-1-Infected Long-Term Non-Progressors have Milder Mitochondrial Impairment and Lower Mitochondrially-Driven Apoptosis in Peripheral Blood Mononuclear Cells than Typical Progressors
Current HIV Research Relationship Between Cigarette Smoking and Other Coronary Risk Factors in Atherosclerosis: Risk of Cardiovascular Disease and Preventive Measures
Current Pharmaceutical Design Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?
Cardiovascular & Hematological Agents in Medicinal Chemistry CA125: An Increasingly Promising Biomarker of Heart Failure
Current Pharmaceutical Design A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy
Current Cardiology Reviews New Insights into the Role of FGF-23 and Klotho in Cardiovascular Disease in Chronic Kidney Disease Patients
Current Vascular Pharmacology Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine Methadone and the Heart: What the Clinician Needs to Know
Current Drug Abuse Reviews FoxO3a Governs Early Microglial Proliferation and Employs Mitochondrial Depolarization with Caspase 3, 8, and 9 Cleavage During Oxidant Induced Apoptosis
Current Neurovascular Research Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls
Current Gene Therapy New Strategies for Managing Anemia of Chronic Kidney Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Therapeutic Applications of Calcium Metabolism Modulation in Heart Disease
Medicinal Chemistry Advancement of Mechanisms of Coxsackie Virus B3-Induced Myocarditis Pathogenesis and the Potential Therapeutic Targets
Current Drug Targets Myocardial Structure and Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Genetics and Heart Failure: A Concise Guide for the Clinician
Current Cardiology Reviews Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy